| Company Name: |
Merck KGaA |
| Tel: |
21-20338288 |
| Email: |
ordercn@merckgroup.com |
|
| | L-Glutamic acid, N-[4-[4-(2-amino-3,4-dihydro-4-oxo-5H-pyrrolo[3,2-d]pyrimidin-5-yl)butyl]-2-fluorobenzoyl]- Basic information |
| | L-Glutamic acid, N-[4-[4-(2-amino-3,4-dihydro-4-oxo-5H-pyrrolo[3,2-d]pyrimidin-5-yl)butyl]-2-fluorobenzoyl]- Chemical Properties |
| density | 1.53±0.1 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | DMSO: 2mg/L, clear | | pka | 3.53±0.10(Predicted) | | form | powder | | color | white to beige | | SMILES | O=C(CC[C@H](NC(C1=CC=C(C=C1F)CCCCN2C=CC(N=C(N3)N)=C2C3=O)=O)C(O)=O)O |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids |
| | L-Glutamic acid, N-[4-[4-(2-amino-3,4-dihydro-4-oxo-5H-pyrrolo[3,2-d]pyrimidin-5-yl)butyl]-2-fluorobenzoyl]- Usage And Synthesis |
| Biological Activity | AGF347 is a potent inhibitor of serine hydroxymethyltransferase 2 (SHMT2) th at inhibits mitochondrial C1 metabolism. It also inhibits cytosolic C1 targets such as SHMT1, GARFTase, and AICARFTase. AGF347 inhibits de novo purine biosynthesis. AGF347 exhibits potent broad spectrum in vitro and in vivo antitumor efficacy. |
| | L-Glutamic acid, N-[4-[4-(2-amino-3,4-dihydro-4-oxo-5H-pyrrolo[3,2-d]pyrimidin-5-yl)butyl]-2-fluorobenzoyl]- Preparation Products And Raw materials |
|